Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

July 27th 2020

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

Gandara Reflects on Current Status of TMB in NSCLC

July 27th 2020

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

July 27th 2020

In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

USPSTF Seeks To Expand Age, Pack-Year LDCT Screening Criteria

July 26th 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at age 50 rather than the current clinical standard of 55 years.

Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

July 24th 2020

Martin Reck, MD, PhD, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Dr. Ramalingam on Next Steps With Nivolumab/Ipilimumab in NSCLC

July 24th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma

July 24th 2020

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLC

July 24th 2020

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Aggarwal Lends Insight on the Use of TKIs and Liquid Biopsies in ALK+ NSCLC

July 24th 2020

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Bunn Breaks Down the Latest With Antibody-Drug Conjugates in Lung Cancer

July 24th 2020

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer

July 23rd 2020

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

New Tools Support Translational Strides in NSCLC

July 23rd 2020

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

July 23rd 2020

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Gandara on the Utility of TMB in NSCLC

July 23rd 2020

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC

July 23rd 2020

In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.

CCC-19 Registry Data Show Increased COVID-19–Associated Mortality in Patients With Cancer

July 22nd 2020

The mortality rate with COVID-19 appears to be higher in patients with cancer—especially those with lung cancer—compared with the general population, and several factors associated with mortality are beginning to emerge.

Pyrotinib Yields Promising Efficacy and Tolerability Among HER2-Altered Solid Tumors

July 16th 2020

The investigational TKI pyrotinib demonstrated encouraging antitumor activity and a manageable toxicity profile in patients with heavily pretreated HER2-mutant non–small cell lung cancer, as well as other advanced solid tumors harboring activating HER2 alterations.

Ramucirumab Combination Expands Lung Cancer Options

July 16th 2020

Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.